|  |
| --- |
| October 22, 2013 |
|  |
| Contact person specialized press Dr. Jürgen KrauterCommunication Health & NutritionPhone +49 6181 59-6847Fax +49 6181 59-76847juergen.krauter@evonik.com |
|  |
| Evonik Industries AGRellinghauser Straße 1-1145128 EssenGermanyPhone +49 201 177-01Telefax +49 201 177-3475www.evonik.de**Supervisory Board**Dr. Werner Müller, ChairmanExecutive BoardDr. Klaus Engel, ChairmanDr. Thomas Haeberle, Thomas Wessel, Patrik Wohlhauser, Ute Wolf, Dr. Dahai YuRegistered office EssenRegistered courtEssen local courtCommercial registry B 19474VAT ID no. DE 811160003 |

**Evonik is granted Written Confirmations for all products of its Wuming site in China**

Evonik was one of the first Active Pharmaceutical Ingredient (API) producing companies in China to be granted Written Confirmations (WC) by the Guangxi Food and Drug Administration for all products manufactured at its Wuming site. These certify that the facility operates in accordance with European Union (EU) requirements for Good Manufacturing Practice (GMP). It enables Evonik to continue exporting APIs from China to Europe even under new EU legislation, the **2011/62/EU** Falsified Medicines Directive.

The responsible local authority, the Guangxi Food and Drug Administration, conducted a series of inspections at the Evonik site in Wuming at the request of Evonik and on behalf of the China Food and Drug Administration (CFDA). This verified compliance with the New Chinese Good Manufacturing Practice and its equivalence to the standards set by the EU and the WHO. Evonik subsequently received Written Confirmations for its entire product portfolio manufactured at the Wuming site.

The certified production facility in China is part of the Health Care Business Line of Evonik Industries and specializes in the production of high-value amino acids and amino acid derivatives.

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion and an operating profit (adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.